Business Description
Alpine Immune Sciences Inc
NAICS : 325412
SIC : 2834
ISIN : US02083G1004
Compare
Compare
Traded in other countries / regions
ALPN.USA34LA.Germany IPO Date
2015-06-17Description
Alpine Immune Sciences Inc is a clinical-stage biopharmaceutical company dedicated to discovering and developing protein-based immunotherapies to treat autoimmune and inflammatory diseases. Its approach includes a proprietary scientific platform that converts native immune system proteins into differentiated, multi-targeted therapeutics. Its pipeline candidates are; ALPN-303, or povetacicept, is a dual antagonist of the B cell activating factor, or BAFF, and a proliferation-inducing ligand, or APRIL, cytokines, which play key roles in the activation, development, and survival of B cells, and ALPN-101, or acazicolcept, is a dual Inducible T cell Costimulator, or ICOS, and CD28 antagonist intended for the treatment of autoimmune and inflammatory diseases.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 19.61 | |||||
| Equity-to-Asset | 0.67 | |||||
| Debt-to-Equity | 0.06 | |||||
| Debt-to-EBITDA | -0.18 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | 2.76 | |||||
| Beneish M-Score | -2.69 | |||||
| WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 111.5 | |||||
| 3-Year EBITDA Growth Rate | 10.1 | |||||
| 3-Year EPS without NRI Growth Rate | 8.8 | |||||
| 3-Year FCF Growth Rate | 12.5 | |||||
| 3-Year Book Growth Rate | 35 | |||||
| Future 3-5Y Total Revenue Growth Rate | 12.67 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 46.49 | |||||
| 9-Day RSI | 42.89 | |||||
| 14-Day RSI | 43.28 | |||||
| 6-1 Month Momentum % | 59.46 | |||||
| 12-1 Month Momentum % | 84.29 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.88 | |||||
| Quick Ratio | 3.88 | |||||
| Cash Ratio | 3.82 | |||||
| Days Sales Outstanding | 7.63 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -35.2 | |||||
| Shareholder Yield % | 1.14 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -224.73 | |||||
| Net Margin % | -201.07 | |||||
| ROE % | -36.6 | |||||
| ROA % | -22.37 | |||||
| ROIC % | -70.03 | |||||
| ROC (Joel Greenblatt) % | -586.4 | |||||
| ROCE % | -28.59 |
GF Value Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 16.47 | |||||
| PB Ratio | 3.39 | |||||
| Price-to-Tangible-Book | 3.39 | |||||
| EV-to-EBIT | -6.51 | |||||
| EV-to-Forward-EBIT | -6.22 | |||||
| EV-to-EBITDA | -6.57 | |||||
| EV-to-Forward-EBITDA | -6.22 | |||||
| EV-to-Revenue | 12.9 | |||||
| EV-to-Forward-Revenue | 8.3 | |||||
| EV-to-FCF | -4.75 | |||||
| Price-to-Net-Current-Asset-Value | 4.64 | |||||
| Price-to-Net-Cash | 4.78 | |||||
| Earnings Yield (Greenblatt) % | -15.36 |
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ALPN
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Alpine Immune Sciences Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 29.123 | ||
| EPS (TTM) ($) | -1.38 | ||
| Beta | 0.96 | ||
| Volatility % | 48.88 | ||
| 14-Day RSI | 43.28 | ||
| 14-Day ATR ($) | 0.63406 | ||
| 20-Day SMA ($) | 11.97975 | ||
| 12-1 Month Momentum % | 84.29 | ||
| 52-Week Range ($) | 4.82 - 14.92 | ||
| Shares Outstanding (Mil) | 49.2 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Alpine Immune Sciences Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Alpine Immune Sciences Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Alpine Immune Sciences Inc Frequently Asked Questions
What is Alpine Immune Sciences Inc(ALPN)'s stock price today?
The current price of ALPN is $11.70. The 52 week high of ALPN is $14.92 and 52 week low is $4.82.
When is next earnings date of Alpine Immune Sciences Inc(ALPN)?
The next earnings date of Alpine Immune Sciences Inc(ALPN) is 2023-11-14 Est..
Does Alpine Immune Sciences Inc(ALPN) pay dividends? If so, how much?
Alpine Immune Sciences Inc(ALPN) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers